JP2009536956A5 - - Google Patents

Download PDF

Info

Publication number
JP2009536956A5
JP2009536956A5 JP2009510180A JP2009510180A JP2009536956A5 JP 2009536956 A5 JP2009536956 A5 JP 2009536956A5 JP 2009510180 A JP2009510180 A JP 2009510180A JP 2009510180 A JP2009510180 A JP 2009510180A JP 2009536956 A5 JP2009536956 A5 JP 2009536956A5
Authority
JP
Japan
Prior art keywords
docetaxel
use according
dose
infusion time
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009510180A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009536956A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/068727 external-priority patent/WO2007134203A2/en
Publication of JP2009536956A publication Critical patent/JP2009536956A/ja
Publication of JP2009536956A5 publication Critical patent/JP2009536956A5/ja
Pending legal-status Critical Current

Links

JP2009510180A 2006-05-12 2007-05-11 抗癌治療法 Pending JP2009536956A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80051006P 2006-05-12 2006-05-12
PCT/US2007/068727 WO2007134203A2 (en) 2006-05-12 2007-05-11 Anticancer treatments with a combination of docetaxel and ecteinascidin

Publications (2)

Publication Number Publication Date
JP2009536956A JP2009536956A (ja) 2009-10-22
JP2009536956A5 true JP2009536956A5 (https=) 2010-05-27

Family

ID=38596836

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009510180A Pending JP2009536956A (ja) 2006-05-12 2007-05-11 抗癌治療法

Country Status (7)

Country Link
US (1) US20100009906A1 (https=)
EP (1) EP2023931A2 (https=)
JP (1) JP2009536956A (https=)
AU (1) AU2007249281A1 (https=)
CA (1) CA2652035A1 (https=)
MX (1) MX2008014404A (https=)
WO (1) WO2007134203A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
BR0115162A (pt) * 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
EP1827500B1 (en) * 2004-10-26 2009-05-06 Pharma Mar S.A., Sociedad Unipersonal Pegylated liposomal doxorubicin in combination with ecteinescidin 743
ATE368461T1 (de) 2004-10-29 2007-08-15 Pharma Mar Sa Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
KR102491180B1 (ko) 2017-04-27 2023-01-20 파르마 마르 에스.에이. 항종양 화합물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
EP1333835A1 (en) * 2000-10-31 2003-08-13 Head Explorer A/S The use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
PL368458A1 (en) * 2001-10-19 2005-03-21 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy

Similar Documents

Publication Publication Date Title
JP2009536956A5 (https=)
Rejhová et al. Natural compounds and combination therapy in colorectal cancer treatment
ES2622559T3 (es) Combinación terapéutica que comprende un inhibidor de cdk y un agente antineoplásico
JP2021512121A5 (https=)
JP2014512356A5 (https=)
RU2010133489A (ru) Применение ингибиторов гамма-секретазы для лечения рака
RU2016102158A (ru) Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака
WO2004043389B1 (en) Methods of treating cancer and related methods
JP2016536352A5 (https=)
JP2020523359A5 (https=)
RU2009127351A (ru) Комбинации антифолатного агента в лечении рака
JP2020523356A5 (https=)
RU2005141408A (ru) Комбинированное применение эктеинасцидина-743 и содержащих платину противоопухолевых соединений
RU2018134167A (ru) Комбинированная терапия для лечения острого миелоидного лейкоза
JP2012522837A5 (https=)
CN103372210A (zh) 小檗碱联合化疗药物在抗肿瘤治疗中的应用
JP2002544231A5 (https=)
JP2019524713A5 (https=)
JP2019511529A5 (https=)
JP2014512355A5 (https=)
JP2008517991A5 (https=)
RU2007119545A (ru) Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
EP1691809A1 (en) Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
RU2018119085A (ru) Схема введения ингибитора фосфатидилинозитол-3-киназы